Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

581. A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients. Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia

A randomized study assessing the systematic search for maxillary sinusitis in nasotracheally mechanically ventilated patients. Influence of nosocomial maxillary sinusitis on the occurrence of ventilator-associated pneumonia PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

582. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

583. Sensitivity and Specificity of Bronchoalveolar Lavage and Protected Bronchial Brush in the Diagnosis of Pneumonia in Pediatric Burn Patients

Sensitivity and Specificity of Bronchoalveolar Lavage and Protected Bronchial Brush in the Diagnosis of Pneumonia in Pediatric Burn Patients PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

584. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. (Abstract)

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. We assessed the effectiveness of a 23-valent pneumococcal vaccine in the prevention of pneumococcal pneumonia and of pneumonia overall in non-immunocompromised middle-aged and elderly people.The prospective, multicentre, double-blind, randomised, placebo-controlled trial was carried out across departments (...) of infectious diseases at six tertiary-care or university hospitals in Sweden. 691 non-immunocompromised patients aged 50-85 years who had been treated as inpatients for community-acquired pneumonia (CAP) were randomly assigned either 23-valent pneumococcal capsular polysaccharide vaccine or placebo (sodium chloride). We used Cox regression models to estimate the relative risks of pneumonia overall and pneumococcal pneumonia for the placebo group compared with the vaccine group.63 (19%) of 339 patients

1998 Lancet Controlled trial quality: predicted high

585. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Full Text available with Trip Pro

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. To compare the feasibility of treatment, safety, and toxicity of intravenous amphotericin B deoxycholate prepared in either glucose or intralipid for empirical antimycotic treatment of neutropenic cancer patients.Single centre stratified, randomised non-blinded phase II study.University hospital providing tertiary clinical care.51 neutropenic (...) patients (leukaemia (35), lymphoma (11), solid tumours (5)) with refractory fever of unknown origin (24) or pneumonia (27).Amphotericin B 0.75 mg/kg/day in 250 ml glucose 5% solution or mixed with 250 ml intralipid 20%, given on eight consecutive days then alternate days, as a 1-4 hour infusion.Feasibility of treatment, subjective tolerance (questionnaire), and objective toxicity (common toxicity criteria of the National Cancer Institute).Study arms were balanced for age, sex, underlying malignancy

1998 BMJ Controlled trial quality: uncertain

586. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. (Abstract)

Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Co-trimoxazole is widely used in treatment of paediatric pneumonia in developing countries, but drug resistance may decrease its effectiveness. We studied the effectiveness of co-trimoxazole compared with that of amoxycillin in pneumonia therapy, and assessed the clinical impact of co-trimoxazole (...) resistance.We recruited 595 children, aged 2-59 months, with non-severe or severe pneumonia (WHO criteria) diagnosed in the outpatient wards of two urban Pakistan hospitals. Patients were randomly assigned on a 2:1 basis co-trimoxazole (n=398) or amoxycillin (n=197) in standard WHO doses and dosing schedules, and were monitored in study wards. The primary outcome was inpatient therapy failure (clinical criteria) or clinical evidence of pneumonia at outpatient follow-up examination.There were 92 (23

1998 Lancet Controlled trial quality: uncertain

587. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Grou (Abstract)

Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Grou Although trimethoprim-sulfamethoxazole is the drug of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tolerate it and must switch to an alternative agent.We conducted a multicenter, open-label, randomized (...) trial comparing daily atovaquone (1500-mg suspension) with daily dapsone (100 mg) for the prevention of P. carinii pneumonia among patients infected with the human immunodeficiency virus who could not tolerate trimethoprim-sulfamethoxazole. The median follow-up period was 27 months.Of 1057 patients enrolled, 298 had a history of P. carinii pneumonia. P. carinii pneumonia developed in 122 of 536 patients assigned to atovaquone (15.7 cases per 100 person-years), as compared with 135 of 521

1998 NEJM Controlled trial quality: uncertain

588. Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia

Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia Ambrose P G, Quintiliani R, Nightingale C H, Nicolau D P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Infusion of cefuroxime for the treatment of community-acquired pneumonia (CAP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Adult patients with a primary diagnosis of CAP. Setting Community teaching hospital. The study was carried out at the Hartford Hospital, Hartford

1998 NHS Economic Evaluation Database.

589. Parenteral vs oral antibiotics in the prevention of serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia: a meta-analysis

Parenteral vs oral antibiotics in the prevention of serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia: a meta-analysis Parenteral vs oral antibiotics in the prevention of serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia: a meta-analysis Parenteral vs oral antibiotics in the prevention of serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia: a meta-analysis Rothrock S G, Green S M (...) , Harper M B, Clark M C, McIlmail D P, Bachur R Authors' objectives To determine whether parenteral antibiotics are superior to oral antibiotics in preventing serious bacterial infections in children with Streptococcus pneumoniae occult bacteraemia. Searching MEDLINE was searched from 1966 through 1996 for articles published in the English language. Bibliographies of articles retrieved were reviewed. Study selection Study designs of evaluations included in the review Articles containing a series

1998 DARE.

590. Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates

Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates Analysis of life-long strategies to prevent Pneumocystis carinii pneumonia in patients with variable HIV progression rates Wynia M K, Ioannidis J P, Lau J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four different strategies for the prevention of Pneumocystis carinii pneumonia (PCP) in AIDS patients were examined. Each strategy comprises at least five different drug regimens, to reflect the fact that patients often switch regimens due to failure or toxicity. The four strategies

1998 NHS Economic Evaluation Database.

591. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients: a pharmaco-economic study based on a meta-analysis

Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients: a pharmaco-economic study based on a meta-analysis Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients: a pharmaco-economic study based on a meta-analysis Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients: a pharmaco-economic study based on a meta-analysis Wessels F (...) , Anderson A N, Ebrahim O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of cephalosporin and amoxicillin/clavulanic acid regimens in the treatment of community acquired pneumonia (CAP). Type of intervention Treatment. Economic

1998 NHS Economic Evaluation Database.

592. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia

Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia Richerson M A, Ambrose P G, Quintiliani R, Bui K Q, Nightingale C H Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intravenous antibiotic monotherapy for hospitalised patients with community acquired pneumonia (CAP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical patients requiring treatment

1998 NHS Economic Evaluation Database.

593. The clinical benefit of in-hospital observation in low-risk pneumonia patients after conversion from parenteral to oral antimicrobial therapy

The clinical benefit of in-hospital observation in low-risk pneumonia patients after conversion from parenteral to oral antimicrobial therapy The clinical benefit of in-hospital observation in low-risk pneumonia patients after conversion from parenteral to oral antimicrobial therapy The clinical benefit of in-hospital observation in low-risk pneumonia patients after conversion from parenteral to oral antimicrobial therapy Rhew D C, Hackner D, Henderson L, Ellrodt A G, Weingarten S R Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Conversion from parenteral to oral antimicrobial therapy for low-risk pneumonia. Type of intervention Other:Observation. Economic study type Cost-effectiveness analysis. Study population

1998 NHS Economic Evaluation Database.

594. Influence of airway management on ventilator-associated pneumonia: evidence from randomized trials

Influence of airway management on ventilator-associated pneumonia: evidence from randomized trials Influence of airway management on ventilator-associated pneumonia: evidence from randomized trials Influence of airway management on ventilator-associated pneumonia: evidence from randomized trials Cook D, De Jonghe B, Brochard L, Brun-Buisson C Authors' objectives To evaluate the influence of ventilator circuit and secretion management strategies on ventilator-assisted pneumonia (VAP). Searching (...) MEDLINE was searched from 1980 to 1997 using the following terms: 'critical care', 'intensive care units', 'pneumonia', 'respiratory tract infection', 'cross infection', 'respiration, artificial ventilators', 'mechanical ventilation', 'randomised controlled trials' and 'prospective trials'. EMBASE was searched using the terms 'pneumonia', 'prevention' and 'control'. Frequently cited articles were identified, SciSearch was used to locate additional trials, and the Cochrane Library and DARE were

1998 DARE.

595. Extending ventilator circuit change interval beyond 2 days reduces the likelihood of ventilator-associated pneumonia

Extending ventilator circuit change interval beyond 2 days reduces the likelihood of ventilator-associated pneumonia Extending ventilator circuit change interval beyond 2 days reduces the likelihood of ventilator-associated pneumonia Extending ventilator circuit change interval beyond 2 days reduces the likelihood of ventilator-associated pneumonia Fink J B, Krause S A, Barrett L, Schaaff D, Alex C G Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) was based on intention to treat or treatment completers only. The health outcome measures consisted of the rate of ventilator-associated pneumonia (VAP) identified using 1988 CDC-defined criteria, average (SD) days to VAP, mortality rate, and risk of occurrence of VAP. A Cox proportional hazards model was performed using ventilator circuit change interval and hospital unit as the potential predictors. In the estimation of relative risk (RR), the adjustment was made for the type of hospital unit (MICU

1998 NHS Economic Evaluation Database.

596. Thoracoscopic surgery for diagnosis of interstitial pneumonia special reference to medicoeconomical effect

Thoracoscopic surgery for diagnosis of interstitial pneumonia special reference to medicoeconomical effect Thoracoscopic surgery for diagnosis of interstitial pneumonia special reference to medicoeconomical effect Thoracoscopic surgery for diagnosis of interstitial pneumonia special reference to medicoeconomical effect Kuda T, Nagamine N, Oshiro J, Matsubara S, Tamashiro M, Sakuda H, Kamada Y, Kuniyoshi Y, Koja K Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Thoracoscopic surgery (TS) and open thoracotomy for the diagnosis of interstitial pneumonia. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Hospitalised patients with interstitial pneumonia. Setting University hospital

1998 NHS Economic Evaluation Database.

597. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis

Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis Omidvari K, de Boisblanc B P, Karam G, Nelson S, Haponik E, Summer W Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using an abbreviated course of intravenous therapy (2-day i.v. antibiotic course followed by switch to oral antibiotics (cefaclor)) for the treatment of hospitalised patients with community-acquired pneumonia

1998 NHS Economic Evaluation Database.

598. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. (Abstract)

Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high. Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries. We did a double-blind randomised trial (...) in The Gambia to assess the efficacy of a Hib conjugate vaccine for the prevention of meningitis, pneumonia, and other invasive diseases due to Hib.Between March, 1993, and October, 1995, 42,848 infants were randomly allocated the conjugate vaccine Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP), or DTP alone at age 2 months, 3 months, and 4 months. Children who presented with signs of invasive Hib were investigated by blood culture and, where appropriate

1997 Lancet Controlled trial quality: predicted high

599. Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. Full Text available with Trip Pro

Randomised, double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles childhood pneumonia. To evaluate the impact on clinical recovery and severity of the addition of large doses of vitamin A to the standard treatment for childhood pneumonia.A randomised, double blind, placebo controlled trial.Study children were recruited at a public hospital in Recife, north east Brazil, an area of marginal vitamin A deficiency.472 children aged 6 to 59 months (...) with clinical diagnosis of pneumonia.200,000 IU (infants) or 400,000 IU (1-4 year olds) of vitamin A in oil or similar capsules of placebo divided into two daily oral doses, in addition to the standard treatment.Duration of the episode and incidence of adverse outcomes.The groups were similar with respect to overall duration of pneumonia and incidence of adverse outcomes. Children who received vitamin A, however, were less likely to have fever by day 3 (P = 0.008) and were 29% less likely to fail to respond

1997 BMJ Controlled trial quality: predicted high

600. Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands

Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands Baltussen R M, Ament A J, Leidl R M, Van Furth R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination against pneumococcal pneumonia. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population A hypothetical group of elderly people. Setting Hospital. The study was carried out in the Netherlands. Dates to which data relate Effectiveness data were collected from studies previously published between 1964 and 1995

1997 NHS Economic Evaluation Database.